Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

482 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    CNIPA "First" Drug Patent Linkage Decision

    Thanks for the heads up from Aaron Wininger of Schwegman Lundberg & Woessner, shortly after the first drug patent linkage decision from the Beijing IP Court, the CNIPA also announced that they have issued their "first" drug patent linkage decision.
    ChinaIntellectual Property
    Toby Mak
    Toby Mak
  • Article

    New Progress In Judicial Protection Of Chinese Patents

    From last year, with the improvement of China's industrial technological level as well as the tremendous changes in the international competitive environment, China's patent protection system and patent protection practices have also been changed and adapted to the same.
    ChinaIntellectual Property
    CCPIT Patent and Trademark Law Office
    CCPIT Patent and Trademark Law Office
Article

Patent Term Adjustment And Drug Patent Term Extension After Amendment To Chinese Patent Law

As we reported in our October 2020 and May 2021 Newsletters, the Fourth Amendment to Chinese Patent Law has become effective from June 1, 2021.
ChinaIntellectual Property
China Sinda Intellectual Property Ltd
China Sinda Intellectual Property Ltd
  • Article

    China update: Orange book-type patent register established as trial version: A start into the new patent linkage system

    This register is a preliminary version for public comment, but the final database is not expected to be much different.
    ChinaIntellectual Property
    Spruson & Ferguson Lawyers
    Spruson & Ferguson Lawyers
  • Article

    ライブ販売の商標侵害に厳罰 山東高裁、懲罰的賠償で抑止強化

    山東省高級人民法院(高裁)はこのほど、2025年の知的財産分野における懲罰的賠償の典型事例を公表した...
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    China Provides "Fast Track" For Certain New Drug Applications

    The State Food and Drug Administration ("SFDA") has been for long experiencing a shortage of manpower to efficiently deal with drug applications in a timely manner.
    ChinaFood, Drugs, Healthcare, Life Sciences
    CMS Cameron McKenna Nabarro Olswang
    CMS Cameron McKenna Nabarro Olswang
  • Article

    GMP Certificate Cancelation: Concern Or Relief?

    On September 24th, Ding Jianhua, director of the China Food and Drug Administration (CFDA) Supervision Department, stated at the 2017 Chinese Pharmaceutical Entrepreneurs, Scientists...
    ChinaFood, Drugs, Healthcare, Life Sciences
    A&Z Law Firm
    A&Z Law Firm
  • Article

    Highlights On New Draft Rules Of Drug Administration

    On May 9, 2022, National Medical Products Administration (NMPA) issued for public comments a draft revision (the "Draft Revision") to the Regulations for the ...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Highlights On The Draft HGR Regulations Implementing Rules

    China began legislating the protection of human genetic resources in 1998, at which time the Ministry of Science and Technology (MOST) and the Ministry of Health jointly formulated...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Quiet On The Set? Forbidding FDA To Take Photographs During An Inspection Can Be Regrettable

    A recent Warning Letter reflects an FDA citation of a company for refusing to permit FDA Investigators to take photographs during an inspection.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Hyman, Phelps, & McNamara
    Hyman, Phelps, & McNamara
  • Article

    Rabbits Rejoice – End of PRC Animal Testing Requirements Nears

    Some brands are not found in China because some cosmetics and body care companies are against animal testing.
    ChinaFood, Drugs, Healthcare, Life Sciences
    King & Wood Mallesons
    King & Wood Mallesons
  • Article

    Relaxation Of Long-Standing Restrictions On Foreign Investment In The Healthcare Sector In China

    The demand for medical services in China is growing, with the country's ageing population set against its potential for economic development.
    ChinaFood, Drugs, Healthcare, Life Sciences
    McDermott Will & Emery
    McDermott Will & Emery
  • Article

    Revised Amendment to the PRC Food Safety Law

    This newsletter discusses the differences between the Amendment and the Revised Amendment, and the underlying rationale.
    ChinaFood, Drugs, Healthcare, Life Sciences
    King & Wood Mallesons
    King & Wood Mallesons
  • Article

    最高人民法院と最高人民検察院、薬品安全をめぐる刑事事件に関する司法解釈を共同発布

    最高人民法院(最高裁)と最高人民検察院(最高検)は3月4日、「薬品の安全危害をめぐる刑事事件における法律適用の若干問題に関する解&#
    ChinaFood, Drugs, Healthcare, Life Sciences
    Kangxin
    Kangxin
  • Article

    1st CNIPA Important Patent Infringement Administrative Decision

    It was reported in Oct 2021 that the CNIPA accepted the first two patent infringement administrative complaints according to the Chinese Patent Law.
    ChinaIntellectual Property
    Toby Mak
    Toby Mak
  • Article

    China's New Medical Device Regulations Bring Big Changes

    The current MDR requires medtech companies to either conduct clinical studies in China or submit clinical evaluation reports illustrating equivalence to previously approved products
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    China Imposes USD 117 Million Fine For Resale Price Maintenance For The First Time In The Pharmaceutical Industry

    On 15 April, 2021, Yangtze River Pharmaceutical Group ("YRPG") was fined RMB 764 million ($116.84 million) by the Chinese antitrust watchdog, representing 3% of its turnover in 2018, hence refreshing the...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Dentons
    Dentons
  • Article

    Highlights of the draft cosmetics supervision regulations

    The CFDA has drafted the Draft for Review to establish a scientific and highly effective regulatory system for cosmetics.
    ChinaFood, Drugs, Healthcare, Life Sciences
    King & Wood Mallesons
    King & Wood Mallesons
  • Article

    Is Cheese Not Welcome Anymore?

    O Parbleu! Thunderclap for the cheese gourmet! Recently China undertakes strengthened regulatory measures which have directly affected the long-term importation of certain types of European cheese...
    ChinaFood, Drugs, Healthcare, Life Sciences
    HFG Law & Intellectual Property
    HFG Law & Intellectual Property
  • Article

    Key 2015 Healthcare And Pharmaceutical Policies

    We have analyzed drug policies with regard to drug pricing and the centralized procurement of drugs in the previous Key 2015 Healthcare and Pharmaceutical Policies: Pharmaceuticals.
    ChinaFood, Drugs, Healthcare, Life Sciences
    King & Wood Mallesons
    King & Wood Mallesons
  • Showing 161–180 of 482 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics